Relay Therapeuticsの空売り状況は、投資家がRelay Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Relay Therapeutics (NASDAQ:RLAY) 株価情報, 空売り情報

RELAY THERAPEUTICS INC

Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Relay Therapeutics Inc

Gevo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported on Wednesday that it has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45642976/gevo-to-sell-luverne-minnesota-ethanol-facility-to-a-e-innovation-will-retain-isobutanol-assets-fo" rel="noreferrer noopener">agreed to sell</a> its ethanol subsidiary, Agri-Energy LLC, to A.E. Innovation LLC for $7 million. The deal includes Gevo&#8217;s idle 18-million-gallon-per-year ethanol plant in Luverne, Minnesota, which has been offline since 2022.
Gevo will retain key isobutanol assets and a portion of the site for future use, enabling the potential production of up to 1 million gallons annually of isobutanol, convertible into specialty chemicals or renewable jet fuel.
A.E. Innovation, a Minnesota-based agriculture group, plans to restart ethanol production and develop the location into a hub for scaling clean fuel technologies.
Also Read: <a href="https://www.benzinga.com/top-stories/25/05/45381191/first-solar-eyes-best-2-day-rally-since-2013-after-gop-tax-plan-spares-key-clean-energy-credits">First Solar Eyes Best 2-Day Rally Since 2013 After GOP Tax Plan Spares Key Clean Energy Credits</a>
The sale provides Gevo with $2 million upfront and $5 million in future payments while reducing approximately $3 million in annual idling costs.
Gevo CEO Patrick Gruber emphasized the opportunity to build new partnerships and highlighted Minnesota&#8217;s leadership in sustainable agriculture.
The restart of ethanol production is expected to benefit Luverne&#8217;s local economy, bolster support for farmers, and reinforce the town&#8217;s role in the renewable energy transition.
Gevo announced yesterday the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45629960/gevo-promotes-leke-agiri-to-chief-financial-officer" rel="noreferrer noopener">appointment</a> of Oluwagbemileke (Leke) Agiri as Chief Financial Officer, effective May 21, 2025. &nbsp;He succeeds L. Lynn Smull, who will take on a new role as Executive Vice President and Senior Advisor to the CEO.
The leadership change reflects Gevo&#8217;s long-term succession planning and positions the company for its next phase of strategic growth.
Related ETFs: Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>), First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>).
Price Action: GEVO shares are trading higher by 1.32% at $1.15 last check on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45429266/solar-security-alert-communication-devices-discovered-in-chinese-inverters-heres-the-stocks-that-could-be-affected">DOE Warns Of Hidden Risks As Chinese Devices In Power Inverters Sparks National Security Concerns: 7 Stocks That Could Be In Focus</a></li>
</ul>
Image via Shutterstock

News

Asset Sales

Movers

GEVO

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

Gevo's Ethanol Plant Sale Cuts $3 Million From Annual Expenses

JP Morgan analyst Sebastiano Petti maintains Telephone and Data Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) with a Overweight and lowers the price target from $56 to $53.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Telephone and Data Sys, Lowers Price Target to $53

Motorola Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 15 years by 7.93% on an annualized basis producing an average annual return of 19.72%. Currently, Motorola Solutions has a market capitalization of $69.91 billion. 
Buying $1000 In MSI: If an investor had bought $1000 of MSI stock 15 years ago, it would be worth $14,926.21 today based on a price of $418.74 for MSI at the time of writing.
<h3>Motorola Solutions's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748446221_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Motorola Solutions Stock In The Last 15 Years

JP Morgan analyst Mark Murphy downgrades Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) from Overweight to Neutral and raises the price target from $24 to $25.

Downgrades

INFA

JP Morgan Downgrades Informatica to Neutral, Raises Price Target to $25

GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Spero Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early for efficacy</a>.&nbsp;
Spero&#8217;s stock price was up 245.89% at last check Wednesday following the news. 
The decision <a target="_blank" href="https://otp.tools.investis.com/generic/regulatory-story.aspx?cid=410&amp;newsid=1948433" rel="noreferrer noopener">follows</a> a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned interim analysis of data from 1,690 patients enrolled in the study.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" rel="noreferrer noopener">GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion</a>
If approved, tebipenem HBr would be the first oral carbapenem antibiotic&nbsp;for patients in the U.S. who suffer from cUTIs. It would add to&nbsp;GSK&#8217;s anti-infectives portfolio and help address the challenges of antimicrobial resistance (AMR).
The trial met the primary endpoint of non-inferiority&nbsp;of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI, including pyelonephritis,&nbsp;on the overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.&nbsp;
The IDMC review did not identify any new safety concerns beyond those reported in other studies with tebipenem. Diarrhea and headache are the two most reported adverse events. 
GSK plans to work with U.S. regulatory authorities to include the data in a filing in 2025.
GSK&#8217;s Chief Scientific Officer Tony Wood said there are limited oral options for drug-resistant infections. This contributes to over $6 billion per year in US healthcare costs.
&nbsp;An estimated 2.9 million cases of cUTIs are treated annually in the U.S. alone. The current standard of care includes carbapenem antibiotics, especially in case of sepsis and allergies or resistance to other antibiotics, but they are only available for IV administration.
Federal funds from the&nbsp;U.S.&nbsp;Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA) support the development of tebipenem HBr.
It is GSK&#8217;s second anti-infective program to be stopped early for efficacy in Phase 3, following the EAGLE 2 and EAGLE 3 trials for gepotidacin in 2022.
In March, the US Food and Drug Administration (FDA) approved&nbsp;GSK&#8217;s Blujepa&nbsp;(gepotidacin) for female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44496482/fda-approves-gsks-oral-antibiotic-for-urinary-tract-infections-for-females-aged-12-years-and-older" rel="noreferrer noopener">tract infections (uUTIs)</a>.
In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics to develop and commercialize tebipenem HBr in all markets except <a target="_blank" href="https://www.benzinga.com/general/biotech/22/09/28960518/spero-therapeutics-stock-almost-doubles-on-gsk-pact-for-its-lead-antibiotic" rel="noreferrer noopener">certain Asian territories</a>.&nbsp;
Price Action: GSK is down 0.33%, trading at around $39.32 per share. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45629452/why-is-teva-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Teva Stock Trading Higher On Tuesday?</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

General

SPRO

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher</a> on Wednesday after the company reported&nbsp;first-quarter&nbsp;2025 results.
The company reported first-quarter adjusted earnings per share of $3.37, missing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45639840/dicks-sporting-goods-reports-first-quarter-results-delivers-record-first-quarter-sales-and-4-5-com" rel="noreferrer noopener">the analyst consensus estimate of $4.34</a>. Quarterly sales of $3.17 billion (+5.2% year over year) missed the Street view of $3.59 billion.
The company reported comparable sales growth of 4.5% in the quarter under review, compared with 5.3% growth a year ago.
Dick&#8217;s reported gross profit of $1.17 billion, higher than $1.09 billion a year ago. Quarterly gross margin expanded to 36.70% from 36.29%.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45477478" rel="noreferrer noopener">What&#8217;s Next For Foot Locker? Analyst Says Dick&#8217;s Deal Is Timely</a>
Dick&#8217;s exited the quarter with cash and equivalents worth $1.04 billion, down from $1.65 billion in the year-ago period. The company generated operating cash flow of $178.05 million, down from $231.71 million. Net inventories totaled $3.57 billion, higher than $3.20 billion a year ago.
On May 15, 2025, the company announced a definitive agreement to acquire Foot Locker for approximately $2.4 billion in equity value.
The deal, expected to close in the second half of 2025, will be financed through a mix of cash, debt, and share issuance, subject to shareholder and regulatory approvals.
&#8220;Earlier this month, we announced our plans to acquire Foot Locker, a move that represents a truly exciting and transformational moment for Dick&#8217;s. For many years we&#8217;ve admired Foot Locker&#8217;s brand and the powerful community they&#8217;ve built in sneaker culture. By bringing our two great brands together, we see the opportunity to create a global leader in the sports retail industry by serving a broader set of athletes,&#8221; said Ed Stack, executive chairman of Dick&#8217;s Sporting Goods.
On May&nbsp;27, the company declared a quarterly dividend in the amount of&nbsp;$1.2125&nbsp;per share, which is payable in cash on June&nbsp;27 to stockholders of record at the close of business on June&nbsp;13, 2025.
Lauren Hobart, president and CEO, reaffirmed the company&#8217;s 2025 outlook, citing a robust start to the year and strong belief in their strategies and operational capabilities while acknowledging the dynamic macroeconomic environment.
The company maintained its FY2025 sales forecast of $13.60 billion to $13.90 billion, compared with the analyst expectations of $13.86 billion.
It reaffirmed the FY2025 GAAP EPS outlook of $13.80 to $14.40, which includes the expected impact from all tariffs currently in effect.
Price Action: DKS shares are trading higher by 0.99% to $175.94 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock" target="_blank" rel="noreferrer noopener">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a></li>
</ul>
Image via Shutterstock

Earnings

Equities

Guidance

Markets

Dick's Sporting Goods Profit Falls Short Of Expectations, Sticks To Annual Outlook Despite Tariffs

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), on Tuesday, inked a deal to acquire Silvus Technologies, Inc. and its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45642246/tjc-announces-sale-of-silvus-technologies-to-motorola-solutions-inc-for-up-to-5-0-billion" rel="noreferrer noopener">subsidiaries for up to $5.0 billion</a>.
The purchase price comprises of $4.4 billion in cash and up to<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45630829/motorola-solutions-to-acquire-silvus-technologies-a-global-leader-in-mission-critical-mobile-ad-ho" rel="noreferrer noopener"> $600.0 million in earnout payments</a>.
Silvu develops software-defined mobile ad-hoc network (MANET) technology that delivers secure voice, video, and data communications without relying on fixed infrastructure.
Its solutions serve global customers across defense, law enforcement, autonomous systems, and enterprise sectors.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45179379/motorolas-resilient-orders-solid-margins-drive-analyst-confidence-despite-tariff-risks" target="_blank" rel="noreferrer noopener">Motorola&#8217;s Resilient Orders, Solid Margins Drive Analyst Confidence Despite Tariff Risks</a>
The deal aims to unite Silvus&#8217; technical expertise with Motorola Solutions' global reach and customer access to accelerate the deployment of high-performance, secure communications worldwide.
The transaction is expected to conclude in the third quarter of 2025.
Greg Brown, chairman and CEO of Motorola Solutions said, &#8220;This acquisition underscores our unwavering conviction that technology is the bedrock for protecting communities, securing borders and defending against today&#8217;s ever evolving threats, whether in the air, on the ground or in the water.&#8221;
&#8221;As a result, we&#8217;re now expanding our intelligent network footprint and powering next-generation security for those who stand on the front lines everywhere.&#8221;
This month, the company reported first-quarter revenue of $2.53 billion, beating the analyst consensus estimate of $2.52 billion, and adjusted EPS of $3.18, beating the <a href="https://www.benzinga.com/news/earnings/25/05/45174267/motorola-faces-stock-decline-as-increased-tariff-related-costs-weigh-on-2025-outlook" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $3.01</a>.
As of March 29, 2025, MSI&#8217;s cash and cash equivalents <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45150326/motorola-solutions-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">stood at $1.56 billion</a>.
Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Telecom ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XTL#NYSE">XTL</a>) and&nbsp;iShares U.S. Telecommunications ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>).
Price Action: MSI shares are down 0.4% at $418.74 at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take" target="_blank" rel="noreferrer noopener">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a></li>
</ul>
Photo: Shutterstock

iShares Dow Jones US Telecommunications Sector Index Fund

Motorola Strengthens Defense Tech Portfolio With $5 Billion Silvus Acquisition

Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares climbed Wednesday after the company voiced support for a slate of new executive orders issued by the White House to boost advanced nuclear <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">energy adoption across the United States.</a>
As part of the White House announcement, Oklo CEO Jacob DeWitte joined President Donald Trump and other industry figures to mark what Oklo called a milestone moment in <a href="https://www.benzinga.com/pressreleases/25/05/b45640943/oklo-supports-executive-orders-to-advance-u-s-nuclear-energy-leadership-and-fuel-security">shaping the future of U.S. energy policy.</a>
The company praised the administration&#8217;s focus on performance-based regulatory reviews and modernization of the Nuclear Regulatory Commission.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45392505/oklo-provides-q1-business-update-nuclear-startup-appoints-new-cto-company-says-its-targeting-plant-operations-in-late-2027-early-2028" rel="noreferrer noopener">Oklo Provides Q1 Business Update: Nuclear Startup Appoints New CTO, Company Says It&#8217;s Targeting Plant Operations In Late 2027, Early 2028</a>
DeWitte emphasized the impact of the executive action, saying it showed a &#8220;clear alignment&#8221; on the need to reform how nuclear technology is licensed, fueled, and constructed.
He added that these moves position nuclear as a cornerstone of American energy strategy going forward.
The orders also require agencies such as the Departments of Energy and Defense to more effectively support the deployment of clean energy technologies.
Meanwhile, Oklo is developing compact fast fission reactors designed to repurpose spent nuclear fuel into stable, emissions-free energy.
The company holds a DOE-issued site use permit and is working through the regulatory process with the NRC.
In a separate announcement, Oklo revealed a partnership with Korea Hydro &amp; Nuclear Power to collaborate on deploying <a href="https://www.benzinga.com/government/regulations/25/05/45625025/oklo-ceo-says-recent-developments-surrounding-nuclear-could-move-company-timelines-forward" target="_blank" rel="noreferrer noopener">its advanced nuclear systems worldwide.</a> The agreement includes joint work on design standardization, manufacturing readiness, and global commercialization of Oklo&#8217;s Aurora powerhouse—a 75 MWe fast reactor facility.
In an interview with CNBC, DeWitte suggested the federal initiatives could speed up Oklo&#8217;s project timelines, citing growing policy alignment and investor interest. He described the executive orders as a &#8220;big commitment&#8221; to making advanced nuclear a near-term reality and said Oklo is positioned to deliver on its goals efficiently and reliably.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, OKLO stock has gained over 400% in the past year. Investors can gain exposure to the stock via&nbsp;VanEck Uranium and Nuclear ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLR#NYSE">NLR</a>).
Price Action: OKLO shares are trading lower by 0.58% to $53.53 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party" target="_blank" rel="noreferrer noopener">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a></li>
</ul>
Photo: Shutterstock

OKLO

What's Going On With Oklo Stock Today?

Macro Economic Events

Global

Economics

Reuters Reports OPEC+ Has Agreed To Use 2025 Oil Output Levels For 2027 Baseline; OPEC+ To Mandate The OPEC Secretariat To Develop A Mechanism To Assess Participating Countries Maximum Sustainable Production Capacity To Be Used As Reference For 2027 Production Baselines; OPEC+ To Meet Next On Nov 30

Jefferies analyst Julien Dumoulin-Smith maintains Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) with a Hold and raises the price target from $11 to $11.25.

Jefferies Maintains Hold on Hawaiian Electric Indus, Raises Price Target to $11.25

Shares of CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) traded lower by 7.49% to $114.74 during Wednesday's session, pulling back from recent all-time highs despite no new company-specific news. The decline comes after recent, strong gains driven by bullish sentiment around the company's <a href="https://www.benzinga.com/news/25/05/45570628/coreweave-crwv-stock-hits-all-time-high-amid-ai-momentum-strategic-deals">growth prospects</a> and strategic developments.
What To Know: On Tuesday, CoreWeave stock jumped following the <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45627509/coreweave-stock-rises-on-government-affairs-appointment-whats-going-on">announcement</a> of Carl Holshouser as Vice President of Government Affairs. Holshouser, a veteran in federal policy and public affairs, was previously EVP at TechNet and held leadership roles at Visa. His appointment signaled CoreWeave's strategic push to strengthen its regulatory and public sector positioning amid increasing government influence on the AI industry.
This leadership move came on the heels of an impressive earnings report and growing investor enthusiasm. This month, CoreWeave <a href="https://www.benzinga.com/news/25/05/45570628/coreweave-crwv-stock-hits-all-time-high-amid-ai-momentum-strategic-deals">reported</a> a staggering 420% year-over-year revenue increase in the first-quarter to $981.6 million, alongside a bullish full-year guidance of up to $5.1 billion. 
A strategic partnership with OpenAI and a significant stake by NVIDIA Corp further fueled the stock's momentum, pushing it to an all-time high of $116.54. Despite Wednesday's pullback, CRWV remains up 175% over the past month as investors continue to bet on the company's AI infrastructure dominance.
Read Also: <a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a>
<h2 class="wp-block-heading">How To Buy CRWV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in CoreWeave&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CRWV has a 52-week high of $125.02 and a 52-week low of $33.52.
Photo: Shutterstock

CRWV

CoreWeave (CRWV) Stock Pulls Back From All-Time High: What's Driving The Volatility?

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 15 years by 7.09% on an annualized basis producing an average annual return of 18.88%. Currently, Arthur J. Gallagher has a market capitalization of $87.65 billion. 
Buying $1000 In AJG: If an investor had bought $1000 of AJG stock 15 years ago, it would be worth $13,842.11 today based on a price of $342.75 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748445311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Arthur J. Gallagher Stock In The Last 15 Years

Reuters Reports OPEC Reaffirms The Level Of Overall Crude Oil Production For OPEC And Non-OPEC Participating Countries In The DOC As Agreed In The 38th OPEC And Non-OPEC Ministerial Meeting Until 31 December 2026; Says It Is To Closely Review Global Oil Market Conditions, Oil Production Levels, And The Level Of Conformity With The DOC, Assisted By The OPEC Secretariat

WIIM

EDBL

Edible Garden shares are trading higher after the company announced it estimates a 25% year-over-year increase in preliminary herb sales during the key Easter holiday period.

DA Davidson analyst Michael Baker maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and raises the price target from $4192 to $4850.

DA Davidson Maintains Buy on AutoZone, Raises Price Target to $4850

The bond market might be whispering, but <a href="https://www.benzinga.com/etfs">ETF investors</a> are already screaming back with a megaphone. 
While Treasury yields rise again in 2025, one theme is becoming impossible to escape: the increasing underperformance of the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) against the Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>). So far into the year, KRE fund has declined more than 3% while XLF is up more than 5%.
The divergence between the two ETFs is getting larger, and it isn&#8217;t a rotational quirk. Rather, it&#8217;s a flashlight signaling the market&#8217;s new fear of regional bank exposure to interest-rate risk and bond portfolio depreciation.
For ETF observers, the XLF-KRE divergence might just be the warning system Wall Street wished it had on hand in early 2023.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45632498/nvidias-40-billion-oracle-win-may-trigger-a-chip-etf-rally">Nvidia&#8217;s $40 Billion Oracle Win May Trigger A Chip-ETF Rally</a>
<h3 class="wp-block-heading">2023: ETFs As Bond Mine Canaries</h3>
The 2023 bank crisis provided a textbook example of duration risk failure. Several regional banks, most prominently Silicon Valley Bank, were dealt crippling losses as bond yields soared. With large positions in long-duration bonds and inadequate hedging, those losses quickly went from &#8220;unrealized&#8221; to &#8220;unmanageable.&#8221;
Investors watching KRE got the message fast. The ETF began to dip days before SVB's name started trending on social media. Meanwhile, XLF held its ground, encouraged by the resilience of large, diversified banks like JPMorgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Bank of America (OTCPK: BACRP).
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28085201/image-361-1024x559.png" alt="" class="wp-image-929871" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28085201/image-361-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28085201/image-361-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28085201/image-361-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28085201/image-361.png 1052w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28090949/image-363-1024x542.png" alt="" class="wp-image-929904" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28090949/image-363-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28090949/image-363-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28090949/image-363-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28090949/image-363.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Now, in 2025, we're seeing a familiar pattern, and ETF investors are once again voting with their dollars.
The Divergence, Quantified
KRE: Trades at par with pre-SVB levels now, but it took more than a year of the collapse for KRE to regain the pre-SVB level.
XLF: has largely rebounded and even moved higher within months of the collapse, showing confidence in large banks.
This divergence is not merely cosmetic. It&#8217;s exposing a structural disconnect in the banking sector that ETFs are highlighting: confidence in big banks, doubt in small ones.
<h3 class="wp-block-heading">What KRE Is Saying</h3>
Investors in ETFs are evidently preparing for further pain, or at least further volatility, among regional banks. Here&#8217;s why:
Rate Risk Continues to Loom: In spite of regulatory pressure to better manage risk, much of the regional banking sector is still exposed to long-duration securities susceptible to price drops with increasing yields.
CRE Exposure: The underlying holdings of KRE feature institutions that are significantly weighted toward commercial real estate lending.
Liquidity Pressure: Even post-2023&#8217;s flight of deposits, smaller banks have few levers to lure and retain capital relative to their giant-bank counterparts.
In short: KRE is the portion of the financial sector that still feels vulnerable. And investors appear to be treating it thus.
<h3 class="wp-block-heading">Meanwhile, XLF Is Rolling</h3>
On the opposite side of the banking ETF fence, XLF has gained from its makeup. Such stalwarts as JPMorgan, Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) did not just shelter from the worst of the 2023 chaos, they benefited from it. For instance Wells Fargo is up more than 100% from the lowest point hit in March 2023 after the SVB collapse. As deposits exited regional banks, they sought safer haven in these institutions.
XLF is now the &#8220;flight-to-safety&#8221; trade in the financials space, a safer-ish wager on institutions with diversified revenue bases, improved risk management, and better regulatory oversight.
<h3 class="wp-block-heading">The ETF Takeaway</h3>
This isn&#8217;t just sector rotation. The KRE-XLF divergence is a living snapshot of the way ETF investors are factoring in systemic risk. It&#8217;s also a cautionary note: when yields increase rapidly, even solid-looking portfolios can plunge.
For tactical ETF traders, the spread may be a trade opportunity, through long/short or volatility trades. For long-term investors, it&#8217;s a barometer for sector risk.
Read Next:<a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45631164/nvidias-q1-earnings-may-mark-a-turning-point-for-chip-etfs"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45631164/nvidias-q1-earnings-may-mark-a-turning-point-for-chip-etfs">Nvidia&#8217;s Q1 Earnings May Mark A Turning Point For Chip ETFs</a></li>
</ul>
Image: Shutterstock

Sector ETFs

ETFs

BACRP

KRE Falls Behind XLF, Sparks SVB Collapse Flashbacks: Are ETFs Sensing Bank Trouble?

CODI

Compass Diversified Holdings shares are trading lower after the company announced it entered into a diversified forbearance agreement and cut its management fees and quarterly dividend. Additionally, the company received a NYSE late filing notice amid an investigation into financial irregularities for its subsidiary.

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to <a href="https://www.benzinga.com/quote/LQDA">improve exercise ability</a>.
In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications.
Liquidia shares fell 5.2% to trade at $14.80 on Wednesday.
These analysts made changes to their price targets on Liquidia following the announcement.
<ul class="wp-block-list">
<li>Wells Fargo analyst Tiago Fauth maintained Liquidia with an Overweight rating and raised the price target from $20 to $23.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained the stock with a Buy and raised the price target from $29 to $35.</li>
<li>Needham analyst Serge Belanger, meanwhile, reiterated Liquidia with a Buy and maintained a $25 price target.</li>
</ul>
Considering buying LQDA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28110518/image-371-1024x603.png" alt="" class="wp-image-930143" style="width:666px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28110518/image-371-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28110518/image-371-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28110518/image-371-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28110518/image-371.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45641814/how-to-earn-500-a-month-from-hp-stock-ahead-of-q2-earnings">How To Earn $500 A Month From HP Stock Ahead Of Q2 Earnings</a></li>
</ul>

LQDA

These Analysts Boost Their Forecasts On Liquidia

CMCO

Columbus McKinnon shares are trading lower after the company reported worse-than-expected Q4 sales results.

SVRA

Savara shares are trading higher. Guggenheim maintained a Buy rating on the stock and Wells Fargo reiterated an Overweight.

Press Releases

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Comments

Relay Therapeutics

空売り

Relay Therapeutics (NASDAQ:RLAY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル